CAJ | 학술논문

目的观察晚期非小细胞肺癌患者应用脐血CIK细胞联合吉西他滨和顺铂的疗效及患者生活质量的变化，评价其临床应用价值。方法将52例确诊的老年晚期非小细胞肺癌患者半随机分成两组。观察组25例给予脐血来源的细胞因子诱导的杀伤细胞静脉输入，联合吉西他滨和顺铂化疗；对照组27例给予吉西他滨和顺铂化疗。结果观察组中部分缓解（PR）6例，稳定（SD）10例，进展（PD）9例，对照组中PR 3例，SD 7例，PD 17例，两组有效率差异有统计学意义（ P＜0.05）。治疗后两组生活质量评分，观察组优于对照组（ P＜0.05）。观察组治疗后不良反应发生率低于对照组（ P＜0.05）。 CIK细胞输注的主要不良反应为发热。结论静脉输注脐血CIK细胞联合吉西他滨和顺铂治疗晚期非小细胞肺癌，是一种新的、安全有效的治疗方法，能有效改善患者的生活质量，不良反应少，值得临床推广应用。
목적관찰만기비소세포폐암환자응용제혈CIK세포연합길서타빈화순박적료효급환자생활질량적변화，평개기림상응용개치。방법장52례학진적노년만기비소세포폐암환자반수궤분성량조。관찰조25례급여제혈래원적세포인자유도적살상세포정맥수입，연합길서타빈화순박화료；대조조27례급여길서타빈화순박화료。결과관찰조중부분완해（PR）6례，은정（SD）10례，진전（PD）9례，대조조중PR 3례，SD 7례，PD 17례，량조유효솔차이유통계학의의（ P＜0.05）。치료후량조생활질량평분，관찰조우우대조조（ P＜0.05）。관찰조치료후불량반응발생솔저우대조조（ P＜0.05）。 CIK세포수주적주요불량반응위발열。결론정맥수주제혈CIK세포연합길서타빈화순박치료만기비소세포폐암，시일충신적、안전유효적치료방법，능유효개선환자적생활질량，불량반응소，치득림상추엄응용。
life,to analyze the clinical value .Methods Fifty-two patients with advanced non -small cell lung cancer were ran-domly divided into two groups .There were 25 patients in the observation group , 27 patients in the control group .The observation group were treated by GP plus CIK cell immunotherapy program and the control group of 27 patients were treated by GP program .Efficacy and adverse reactions were evaluated .QLQ-LC13 scale was used before and after treatment to assess the quality of life .Results The observation group showed PR in 6 cases, SD in 10 cases, PD in 9 cases, the control group showed PR in 3 cases, SD in 7 cases, PD in 17 cases.The difference between the two groups was statistically significant( P<0.05 ) .After treatment , the life quality scores in the observation group was better than that in the control group ( P<0.05 ) .The adverse reaction in the observation group was lower than the control group(P<0.05).In the observed group, the probability of fever was higher than that of the control group (P<0.05 ) .Conclusion The treatment of cord blood cytokine -induced killer cells combined with gemcitabine and cispl-atin for advanced non-small cell lung cancer patients is safe and effective .It can improve quality of life of the patients with advanced non-small cell lung cancer .The treatment will be worth popularizing in clinical applications . <br> Objective To observe the efficacy of cord blood cytokine-induced killer cells combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer ,and to study patients′quality of life,to analyze the clinical value .Methods Fifty-two patients with advanced non -small cell lung cancer were ran-domly divided into two groups .There were 25 patients in the observation group , 27 patients in the control group .The observation group were treated by GP plus CIK cell immunotherapy program and the control group of 27 patients were treated by GP program .Efficacy and adverse reactions were evaluated .QLQ-LC13 scale was used before and after treatment to assess the quality of life .Results The observation group showed PR in 6 cases, SD in 10 cases, PD in 9 cases, the control group showed PR in 3 cases, SD in 7 cases, PD in 17 cases.The difference between the two groups was statistically significant( P<0.05 ) .After treatment , the life quality scores in the observation group was better than that in the control group ( P<0.05 ) .The adverse reaction in the observation group was lower than the control group(P<0.05).In the observed group, the probability of fever was higher than that of the control group (P<0.05 ) .Conclusion The treatment of cord blood cytokine -induced killer cells combined with gemcitabine and cispl-atin for advanced non-small cell lung cancer patients is safe and effective .It can improve quality of life of the patients with advanced non-small cell lung cancer .The treatment will be worth popularizing in clinical applications .